Composition for use in the treatment of ApoL1-associated disease
AssigneeVertex Pharmaceuticals Incorporated
InventorsKarl Skorecki, Ira Bavli-Kertselli, Tali Shemer, Etty Kruzel-Davila, Orly Tabachnikov
Life of this patent
Estimating the term…
Abstract
The invention in some embodiments thereof, relates to the field of compositions and/or pharmaceutical compositions comprising one or more biologically active compound, and is directed to methods of using same such as for treating an ApoL1 related disease or a disorder in a subject.
Claims7
A method for treating ApoL1 associated kidney disease comprising administering to a subject in need thereof a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof, wherein the compound is represented by Formula 1D:
- or Formula 4.1:
- wherein:
- each R is independently chosen from substituted or non-substituted C3-C6 cycloalkyl, substituted or non-substituted 5- to 6-membered heteroaryl, and substituted or non-substituted phenyl;
- each R1 is independently chosen from substituted and non-substituted C1-C3 alkyl;
- R3 is absent;
- R4 is hydrogen;
- each R′ is independently chosen from and C1-C3 alkyl, or R′ is absent;
- each X is independently N or CH;
- ------ represents a single or a double bond;
- and
- each n is 0 or 1.
A method for treating ApoL1 associated kidney disease comprising administering to a subject in need thereof a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof, wherein the compound is
A compound which is:
- or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.